HK

Hans G. Klingemann

NA Nantkwest: 4 patents #1 of 7Top 15%
IM Immunitybio: 2 patents #5 of 15Top 35%
NI Nant Holdings Ip: 2 patents #11 of 26Top 45%
NA Nantcell: 2 patents #4 of 8Top 50%
📍 Culver City, CA: #6 of 160 inventorsTop 4%
🗺 California: #1,782 of 66,859 inventorsTop 3%
Overall (2021): #13,265 of 548,734Top 3%
8
Patents 2021

Issued Patents 2021

Showing 1–8 of 8 patents

Patent #TitleCo-InventorsDate
11207392 Coordinated multi-prong cancer therapy Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Laurent H. Boissel, Barry J. Simon 2021-12-28
11207350 Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Tien Lee, Barry J. Simon, Laurent H. Boissel 2021-12-28
11129850 Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Laurent H. Boissel, Nathan T. Schomer 2021-09-28
11077143 Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells Laurent H. Boissel, Abhijit Dandapat 2021-08-03
11071774 Nant cancer vaccine Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh, Laurent H. Boissel 2021-07-27
11058723 Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Laurent H. Boissel, Nathan T. Schomer 2021-07-13
11000550 Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer Tien Lee, Barry J. Simon, Laurent H. Boissel 2021-05-11
10960024 Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Laurent H. Boissel, John H. Lee, Nathan T. Schomer 2021-03-30